High volume intraperitoneal chemotherapy (?Belly bath?) for ovarian cancer
Authors:
- 1 January 1978
- journal article
- clinical trial
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 1 (3) , 161-166
Abstract
The currently accepted therapies for ovarian cancer have produced only limited numbers of extended complete remissions in advanced-stage disease. Studies of high-volume intraperitoneal chemotherapy have been initiated to define the toxicology, pharmacokinetics, and the therapeutic effectiveness of this treatment modality. This technique has been virtually ignored until recently, because little success has been achieved with it except in one study (Rutledge, 1966), in which large intraperitoneal fluid volumes were used. The general lack of success probably reflects inadequate attention to physiologic and pharmacologic principles of drug distribution and absorption in a space as large as the peritoneal cavity. Biomedical engineers, pharmacologists, and clinicians at the NCI have cooperated in the development of a rational chemotherapy for ovarian cancer. Following mathematical pharmacokinetic modeling and toxicologic studies in rat, a Phase I clinical trial of intraperitoneal methotrexate administered in large volumes of dialysis fluid was initiated. Results in three patients confirm the practicality of this approach, and further investigation is warranted.Keywords
This publication has 22 references indexed in Scilit:
- The effect of volume on the distribution of substances instilled into the peritoneal cavityGynecologic Oncology, 1978
- PHARMACOKINETIC RATIONALE FOR PERITONEAL DRUG ADMINISTRATION IN TREATMENT OF OVARIAN CANCER1978
- Methotrexate Disposition in Humans: Case Studies in Ovarian Cancer and Following High-Dose InfusionDrug Metabolism Reviews, 1978
- Kinetics and Mechanisms of Drug Action on Microorganisms XXIII: Microbial Kinetic Assay for Fluorouracil in Biological Fluids and Its Application to Human PharmacokineticsJournal of Pharmaceutical Sciences, 1977
- Competitive protein binding assay for methotrexate.Proceedings of the National Academy of Sciences, 1975
- Peritoneoscopy: A Valuable Staging Tool in Ovarian CarcinomaAnnals of Internal Medicine, 1975
- Interdisciplinary Approach to Advanced Ovarian CancerSurgical Clinics of North America, 1974
- Treatment of Ovarian Carcinoma: Possibilities for ProgressNew England Journal of Medicine, 1972
- A bacteriologically safe peritoneal access device.1968
- Re-evaluation of methotrexate as an anticancer drug.1967